Evidence map›Paper›PMID 24349068›Full record

ArticlePloS one2013

Gene expression analysis of PTEN positive glioblastoma stem cells identifies DUB3 and Wee1 modulation in a cell differentiation model.

Stefano Forte, Alfredo Pagliuca, Eugenia T Maniscalchi, Rosario Gulino, Giovanna Calabrese, Lucia Ricci-Vitiani, Roberto Pallini, Michele Signore, Rosalba Parenti, Ruggero De Maria and 1 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Profiling Glioma Stem Cell Dynamics via 3D-Based Cell Cycle Reporter Assays.Methods in molecular biology (Clifton, N.J.) · 2025
    Article
  4. Frontiers in oncology · 2022
    Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Stefano ForteIOM Ricerca srl, Viagrande, Italy.
Alfredo PagliucaDepartment of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.
Eugenia T ManiscalchiDepartment of Biomedical Sciences, University of Catania, Italy.
Rosario GulinoIOM Ricerca srl, Viagrande, Italy.
Giovanna CalabreseIOM Ricerca srl, Viagrande, Italy.
Lucia Ricci-VitianiDepartment of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.
Roberto PalliniInstitute of Neurosurgery, Catholic University School of Medicine, Rome, Italy.
Michele SignoreDepartment of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.
Rosalba ParentiDepartment of Biomedical Sciences, University of Catania, Italy.
Ruggero De MariaItalian National Cancer Institute 'Regina Elena', Rome, Italy.
Massimo GulisanoDepartment of Biomedical Sciences, University of Catania, Italy.
Istituto Superiore di Sanità · ITUniversity of Catania · ITUniversità Cattolica del Sacro Cuore · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The term astrocytoma defines a quite heterogeneous group of neoplastic diseases that collectively represent the most frequent brain tumors in humans. Among them, glioblastoma multiforme represents the most malignant form and its associated prognosis is one of the poorest among tumors of the central nervous system. It has been demonstrated that a small population of tumor cells, isolated from the brain neoplastic tissue, can reproduce the parental tumor when transplanted in immunodeficient mouse. These tumor initiating cells are supposed to be involved in cancer development and progression and possess stem cell-like features; like their normal counterpart, these cells remain quiescent until they are committed to differentiation. Many studies have shown that the role of the tumor suppressor protein PTEN in cell cycle progression is fundamental for tumor dynamics: in low grade gliomas, PTEN contributes to maintain cells in G1 while the loss of its activity is frequently observed in high grade gliomas. The mechanisms underlying the above described PTEN activity have been studied in many tumors, but those involved in the maintenance of tumor initiating cells quiescence remain to be investigated in more detail. The aim of the present study is to shed light on the role of PTEN pathway on cell cycle regulation in Glioblastoma stem cells, through a cell differentiation model. Our results suggest the existence of a molecular mechanism, that involves DUB3 and WEE1 gene products in the regulation of Cdc25a, as functional effector of the PTEN/Akt pathway.

Indexed as

AdultAgedCell Cycle ProteinsCell DifferentiationEndopeptidasesFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMaleMiddle AgedNeoplastic Stem CellsNuclear ProteinsProtein-Tyrosine KinasesPTEN PhosphohydrolaseCell Cycle ProteinsEndopeptidasesNuclear ProteinsProtein-Tyrosine KinasesPTEN PhosphohydrolasePTEN protein, humanUSP17L2 protein, humanWEE1 protein, human

Identifiers

PMID24349068
PMCPMC3861258
OpenAlexW2111410337

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.